https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34932 Wed 24 Nov 2021 15:51:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29089 Thu 26 Jul 2018 14:44:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33646 1500 American College of Surgeons Commission on Cancer-accredited facilities, patients receiving PECT were shown to survive longer than those receiving POCRT.]]> Thu 17 Feb 2022 09:28:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20038 Sat 24 Mar 2018 07:50:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4965 50% cells positive) was displayed mostly in HGD and AdenoCa (46.7% and 42.3%, respectively). Ki-67 index increased with the severity of dysplasia and labeling extended from the lower third of the crypts to the superficial epithelium. The frequency of AMACR-positivity was 12% in BE, 47.1% in IND, 44.4% in LGD, 93.3% in HGD, and 96.2% in AdenoCa. The intensity and extent of AMACR staining also increased with the severity of dysplasia. Aberrant p16 and high-cyclin D1 expression may reflect early genetic events during the progression of Barrett-associated carcinogenesis. Cytoplasmic staining of p16 is specific. It may represent a different pathway of p16 dysfunction. The pattern and extent of Ki-67 staining and AMACR overexpression are useful additional parameters for identifying dysplasia in BE.]]> Sat 24 Mar 2018 07:46:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26599 Sat 24 Mar 2018 07:33:57 AEDT ]]>